This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $4,169.59, is for the delivery of XTANDI 80 MG TABLET 60S, a prescription medication. The contract has an ultimate completion date of December 16, 2024.
DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a wide range of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the medical supply needs of military healthcare facilities and veterans' medical centers nationwide. The company holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items.
This particular delivery order contract is not associated with any set-aside designation, allowing DMS Pharmaceutical Group Inc. to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains.
Generated 3/14/25, 9:54 AM